Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study.

Jingyuan ChenJun LuoXiaojie YangPeng LuoYusi ChenZilu Li Jiang Li

Published in: International journal of general medicine (2021)

Our results suggested that it is safe and tolerable for stable PAH patients to transition from bosentan to ambrisentan without influencing hematologic parameters or heart function.

Keyphrases

pulmonary arterial hypertension
pulmonary artery
pulmonary hypertension
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
heart failure
prognostic factors